<DOC>
	<DOCNO>NCT00654160</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan , fluorouracil , leucovorin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I trial study side effect best dose irinotecan give together fluorouracil leucovorin treat patient advanced gastrointestinal cancer .</brief_summary>
	<brief_title>Irinotecan , Fluorouracil , Leucovorin Treating Patients With Advanced Gastrointestinal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose irinotecan hydrochloride FOLFIRI respective UGT1A1 TA indel genotype grouping ( group 1 [ 7/7 , 7/8 , 8/8 ] , group 2 [ 6/7 , 5/7 , 5/8 ,6/8 ] , group 3 [ 6/6 , 5/6 , 5/5 ] ) . Secondary - Determine molecular basis toxicity , UGT1A1 variant , FOLFIRI-treated cancer patient . - Determine pharmacodynamic molecular profile cell signal pathway associate development severity early late specific toxicity cancer patient treat FOLFIRI . OUTLINE : This dose-escalation study irinotecan hydrochloride . Patients stratify accord genotype UGT1A1 TA indel . - Group 1 ( TA genotype 7/7 , 7/8 , 8/8 ) : Patients receive irinotecan hydrochloride IV 90 minute leucovorin calcium IV 2 hour day 1 fluorouracil IV bolus 5 minute follow IV continuously 46 hour day 1-3 . - Group 2 ( TA genotype 6/7 , 6/7 , 5/8 , 6/8 ) : Patients receive treatment group 1 high initial dose irinotecan hydrochloride . - Group 3 ( TA genotype 5/5 , 5/6 , 6/6 ) : Patients receive treatment group 2 . In group , treatment repeat every 14 day absence disease progression unacceptable toxicity . Patients undergo blood collection baseline periodically study pharmacokinetics , dihydropyridine deaminase enzyme assay , pathway expression analysis . After completion study treatment , patient follow every 6 week 2 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Appendiceal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy confirm diagnosis gastrointestinal cancer Advanced , unresectable disease Confirmation UGT1A1 TA indel genotype Measurable evaluable ( nonmeasurable ) disease Measurable disease define ≥ 1 lesion accurately measure ( long diameter record ) ≥ 2.0 cm conventional technique ≥ 1.0 cm spiral CT scan Clinical lesion consider measurable superficial ( e.g. , skin nodule , palpable lymph node ) Lesions chest xray acceptable measurable lesion clearly define surround aerated lung The following consider nonmeasurable disease : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/ pulmonis Inflammatory breast disease Abdominal mass ( follow CR scan MRI ) Cystic lesion All lesion ( site disease ) , include small lesion ( long diameter &lt; 2.0 cm conventional technique &lt; 1.0 cm spiral CT ) No known central nervous system metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Inclusion criterion Life expectancy ≥ 12 week . ECOG performance status 02 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ SGOT ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5 time ULN liver metastasis ) Total Bilirubin ≤ ULN patient group 3 ≤ 2.0 time ULN patient group 1 2 Hemoglobin ≥ 9.0 g/dL Creatinine ≤ 1.5 time ULN creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception duration study treatment Willing provide blood sample mandatory translational study Exclusion criterion Known allergy irinotecan hydrochloriderelated agent ( e.g. , topotecan ) , 5fluorouracil , and/or leucovorin calcium Active uncontrolled infection Evidence serious intercurrent illness ( e.g. , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) PRIOR CONCURRENT THERAPY : Recovered toxicity More 4 week since prior major surgery More 2 week since completion prior radiotherapy No prior radiotherapy &gt; 25 % bone marrow More 2 week since prior cytotoxic chemotherapy , biologic therapy , immunotherapy No concurrent sargramostim ( GMCSF )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>stage IIIB anal cancer</keyword>
	<keyword>stage IV anal cancer</keyword>
	<keyword>recurrent anal cancer</keyword>
	<keyword>carcinoma appendix</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>regional gastrointestinal carcinoid tumor</keyword>
	<keyword>gastrointestinal stromal tumor</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>small intestine lymphoma</keyword>
</DOC>